PROTACs for Collateral Degradation: Is It Time to Back Up the Bus?

Area of Science:

• Drug development
• Molecular biology
• Biochemistry

Background:

• Off-target effects are generally considered detrimental in pharmaceutical research and development.
• The utility of off-target activities in drug design is an underexplored area.
• Proteolysis Targeting Chimeras (PROTACs) and similar molecular degraders offer novel therapeutic modalities.

Purpose of the Study:

• To investigate the potential advantages of off-target effects in drug development.
• To explore scenarios where targeting multiprotein complexes, rather than single proteins, is therapeutically relevant.
• To re-evaluate the role of off-target activities in the context of novel degraders like PROTACs.

Main Methods:

• Literature review and theoretical analysis of drug-target interactions.
• Case study analysis of existing PROTACs and molecular degraders.
• Bioinformatic analysis of protein-protein interaction networks.

Main Results:

• Off-target effects can be advantageous for PROTACs and degraders when the therapeutic goal involves modulating the function of multiprotein complexes.
• The activity of a targeted protein may be less critical than the collective function of a protein complex in certain disease contexts.
• Understanding complex-level interactions can guide the design of more effective degraders.

Conclusions:

• The conventional view of off-target effects as solely undesirable needs revision, particularly for complex-targeting agents.
• PROTACs and other degraders present opportunities to leverage off-target activities for therapeutic benefit.
• Future drug development strategies should consider the modulation of multiprotein complexes through carefully designed off-target interactions.